RecruitingPhase 2NCT06046222
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
Studying Eosinophilic granulomatosis with polyangiitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NS Pharma, Inc.
- Intervention
- NS-229(drug)
- Enrollment
- 45 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- National Jewish Health, Denver, Colorado, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- University of Alberta, Edmonton, Alberta, Canada
- St Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada
- University of Toronto, Toronto, Ontario, Canada
- CHU Nice, Nice, France
- Hopital Cochin, Paris, France
- Chu Rangueil, Toulouse, France
- Medius Kliniken gGmbh, Kirchheim unter Teck, Studienzentrale, Germany
- Istituto Auxologico Italiano IRCCS, Milan, Italy
- +15 more locations on ClinicalTrials.gov
Collaborators
Nippon Shinyaku Co., Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06046222 on ClinicalTrials.govOther trials for Eosinophilic granulomatosis with polyangiitis
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE4NCT07343661Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPAAzienda Ospedaliero Universitaria di Cagliari
- RECRUITINGPHASE3NCT06512883A Trial to Investigate Benralizumab in Children With Eosinophilic DiseasesAstraZeneca
- ACTIVE NOT RECRUITINGPHASE2NCT06230354Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With PolyangiitisImperial College London
- RECRUITINGNCT06298448eGPA and Local Inflammation Within the Ear, Nose and Throat AreaUniversity Medical Center Groningen
- RECRUITINGPHASE2, PHASE3NCT05979051A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）Guangdong Hengrui Pharmaceutical Co., Ltd
- ACTIVE NOT RECRUITINGPHASE3NCT05263934Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)GlaxoSmithKline
- ACTIVE NOT RECRUITINGPHASE3NCT05030155Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)Assistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE2NCT02947945Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) StudyNational Jewish Health
See all trials for Eosinophilic granulomatosis with polyangiitis →